Introduction
Breast cancer is the most common malignancy and a major cause of cancer-related deaths among women in the Western Europe and United States (Wingo et al., 1998) . Together with acquired or inherited gene defects (i.e. oncogenes, tumor suppressor genes), other parameters are involved such as environmental-dietary factors and overall hormonal status (Nicholson et al., 1999) . It is known that hormones and growth factors play an important role in breast cancer pathogenesis (Dickson et al., 2000; Dankort and Muller, 2000) , and that cancer cells may acquire the ability to synthesize the growth factors to which they are responsive, acting by an autocrine-paracrine pathway (Ethier, 1995) .
Prolactin (PRL) is a polypeptidic hormone secreted mainly by the anterior pituitary, that exerts multiple biological activities (reviewed by Bole-Feysot et al., 1998) . In the mammary gland, it participates in lobulo-alveolar development, alveolar cell growth and milk protein synthesis, acting as a proliferation and dierentiation factor (depending on the development stage). Although in rodents it has been clearly demonstrated that PRL plays a role in inducing and favoring breast cancer (Wennbo et al., 1997; Vomachka et al., 2000) , its involvement in human breast neoplasia has been long debated (Vonderhaar, 1998; Gon et al., 1999a; Wennbo and Tornell, 2000) . Recently, an epidemiological study has made clear the signi®cant correlation between plasma PRL levels and increased breast cancer risk in postmenopausal women (Hankinson et al., 1999) . Moreover, several studies have demonstrated that human mammary epithelial cells synthesize and/or secrete hPRL (Clevenger et al., 1995; Ginsburg and Vonderhaar, 1995; Shaw-Bruha et al., 1997; Touraine et al., 1998) , that they proliferate in response to the hormone (Ginsburg and Vonderhaar, 1995) and that neoplastic tissue express higher levels of PRL receptor (PRLR) than normal adjacent tissue (Touraine et al., 1998) . All these ®ndings support the idea that PRL plays an autocrine-paracrine proliferative role in the mammary gland, and thereby may be involved in breast tumor progression. Some molecular bases of this eect have been elucidated in the past few years. In mammary epithelial cells (tumor and normal), PRL induces phosphorylation (and activation) of the PRLR-associated tyrosine kinase JAK2, which in turn phosphorylates latent cytoplasmic transcription factors STAT5, STAT3 and STAT1 (DaSilva et al., 1996; Schaber et al., 1998) . Other pathways are also activated by PRL in mammary epithelial cells, which involve the Ras/Raf/MAP kinase (Das and Vonderhaar, 1996a,b; Schaber et al., 1998) , the Protein Kinase C (Waters and Rillema, 1989; Banerjee and Vonderhaar, 1992) and the Focal Adhesion Kinase-paxillin (Canbay et al., 1997) pathways (for a review, Llovera et al., 2000) . Based among others on the use of speci®c kinase inhibitors, it has been shown that the JAK/STAT and MAPK pathways play a critical role in PRL-induced proliferation of mammary epithelial cells Vonderhaar, 1996a,b, 1997) .
Preventing the autocrine/paracrine proliferative eect of hPRL by targeting its expression in mammary epithelial cells is currently compromised by the lack of known negative regulator of PRL gene expression in this tissue. Indeed, dopamine, the main down-regulator of hPRL expression in the pituitary, appears to be inecient in regulating hPRL synthesis in extrapituitary sites (Ben-Jonathan et al., 1996) . Rather, targeting the activation of the PRLR by using antagonists has emerged as a more reasonable strategy concerning the current state of the art (Gon et al., 1999a) . The human PRLR is a member of the cytokine receptor superfamily (Kelly et al., 1991) . Its natural ligands are hPRL, placental lactogen (hPL) and, in the presence of zinc, human growth hormone (hGH), which all activate the receptor by inducing its dimerization (Gon et al., 1996a) . Based on this mechanism of activation, we and others developed various PRLR antagonists by designing point mutated hormone analogs unable to induce proper PRLR dimerization (for reviews, Wells, 1996; Gon et al., 1996a) . Regarding the human family of PRLR ligands, the ®rst reports describing the antagonistic properties of hormone analogs were provided by the group of James Wells for hGH and hPL (Fuh et al., 1992; Fuh and Wells, 1995) and by our group for hPRL (Gon et al., 1996b) . Two hPRL analogs, namely A22W-hPRL and G129R-hPRL, were shown to antagonize hPRL in a self-designed bioassay based on 293 ®broblastic cells stably transfected with sequences encoding the human receptor and a PRL-responsive reporter gene (Gon et al., 1996b) . The next step in our investigation was thus to evaluate whether the antagonistic properties of these analogs could also be exerted on hPRLR-mediated eects in human breast cancer cells. This was performed by analysing the action of the antagonist, alone or in competition with WT hPRL, in cell proliferation assays and on the two major hPRLRtriggered signaling cascades presumably involved in this eect (JAK/STAT and MAPK). This study (i) provides several lines of evidence that G129R-hPRL lacks intrinsic ability to activate the hPRLR, but antagonizes hPRL-induced proliferation of breast cancer cells; (ii) is the ®rst demonstration at the molecular level that hPRL antagonists disrupt hPRLactivated signaling events in target cells; (iii) suggests that these observations may be extended to all mammary tumor cells expressing the PRLR since they were performed in four dierent cell lines, irrespective of their estrogen receptor status.
Results
Binding of hPRL and G129R-hPRL to T-47D and T-47Dco human breast cancer cells Scatchard analysis of hPRL and G129R-hPRL was performed on T-47D (not shown) and T-47Dco cell homogenates (Figure 1a) , and the anities (K d ) calculated were 5.4610 710 M for hPRL and 3610
79 M for G129R-hPRL, irrespective of the cell line used. The number of hPRLR per cell is 29 500 for T-47Dco and 21 500 for T-47D clones.
Design of WST-1 proliferation assay in microplates
The routine conditions of the proliferation assay (see Materials and methods) were determined after testing various parameters of the assay (not shown): type of culture medium, type of serum (FCS or CSS), serum concentration (0 ± 10%), cell density (1500 ± 80 000, counted on hemocytometer), time of proliferation (2 ± 7 days) and time of the WST-1 reaction (1 ± 8 h). The colorimetric WST-1 assay is proportional to the cell number, with the linear part of the sigmoid curve in the range of *50 000 to *150 000 cells per well (OD 450 between *1 and *3.5), after 2 ± 4 h of reaction (longer times reduced the range of cell number in which a linear correlation is obtained). Therefore, under routine conditions, 30 000 cells were plated in each well to fall into this range after 3 days of cell proliferation (cells proliferate slightly in non stimulated controls due to the presence of 0.5 ± 1% CSS; see Figure 2 ). For antagonistic experiments, cells were stimulated using a ®xed concentration of hPRL (0.1 mg/ml) competed with increasing concentrations of G129R-hPRL (c). After 3 days of incubation, 10 ml of WST-1 were added to each well and OD 450 nm was measured in a microplate reader at 2 h time intervals (a reference wavelength of 630 nm was used to normalize plate variability). Results are expressed as a percentage of the maximal eect of hPRL. Each point represents the mean of at least three independent experiments performed in triplicate (average IC 50 =0.4 mg/ml) Figure 2 Cell cycle analyses on T-47D and T-47Dco cells. T-47D and T-47Dco cells were serum deprived for 24 h, then incubated in 10% FCS (positive control), or in 0.5% CSS in the absence or in the presence of 1 mg/ml hPRL, 10 mg/ml G129R-hPRL, or both hormones combined. Cell cycle analyses were performed after 24 h, 48 h or 72 h of treatment. (a) Pro®les obtained after 24 h using T-47D cells. DNA content (FLA-2) versus cell number is presented in each panel. From left to right, numbers indicate the percentage of cells in apoptosis (area below 400 on X axis), in G 0 /G 1 (peak centered on 400 on X axis) or in S/M phase (area above 400 on X axis). Note that G129R-hPRL has no eect per se compared to the assay medium with respect to cell division or apoptosis. In contrast, it completely inhibits the proliferative eect of hPRL. (b) The percentage of cells in proliferation (S/M phase) after 24 h, 48 h and 72 h for both T-47D and T-47Dco cells is shown Agonistic and antagonistic properties of hPRL and G129R-hPRL on cell proliferation
We ®rst tested the responsiveness of T-47D and T47Dco cell lines to hPRL stimulation. hPRL-induced proliferation of T-47Dco cells (OD 450 increased by 2.5 ± 3-fold) was systematically more pronounced than for the T-47D clone (OD 450 increased by *1.4-fold) (not shown). Extrapolation of OD 450 values to cell numbers re¯ects more than one doubling of cell population for T-47Dco cells, compared to *40% increase of cell number for the T-47D clone. These values are in good agreement with previous reports using T-47D cells Das and Vonderhaar, 1996b; Chen et al., 1999) . We disregarded the possibility that the proliferative eect of exogenous hPRL could be partly masked by signi®cant endogenous secretion of hPRL (Clevenger et al., 1995; Ginsburg and Vonderhaar, 1995) since the quanti®cation of lactogens present in conditioned media of T-47D and T-47Dco cells was 50.5 ng/ml (per day/10 6 cells), as estimated by IRMA or Nb2 cell proliferation assay (not shown). Due to their higher responsiveness, T-47Dco cells were used to perform the proliferation assays involving G129R-hPRL.
Human PRL induced T-47Dco proliferation in a dose-dependent manner, with an eect starting at 10 ng/ml (*20% of maximal eect) and reaching its maximum at 0.5 ± 1 mg/ml of hPRL ( Figure 1b) . In contrast, G129R-hPRL produced only a very weak response (515% of hPRL maximal eect). When 100 ng/ml hPRL were competed with increasing concentrations of G129R-hPRL, the analog inhibited hPRL-induced cell proliferation dose-dependently, with an average IC 50 of *400 ng/ml ( Figure 1c ).
Data obtained in WST-1 bioassays were totally con®rmed by cell cycle analyses (FACS) for both T-47D and T-47Dco cell lines. As shown in Figure 2a , 23% of T-47D cells were in cell cycle progression (S/M phase) after 24 h treatment using hPRL (1 mg/ml), a value intermediate between that observed in the assay medium containing 0.5% CSS (11% of proliferative cells) and in the growth medium containing 10% FCS (33% of proliferative cells). Expectedly, G129R-hPRL had no eect compared to the assay medium (12% of proliferative cells), whereas a 10 : 1-fold molar excess of the analog markedly inhibited the proliferative eect of hPRL (13% of proliferative cells). Even after 48 h, T-47D cells treated with G129R-hPRL, alone or in competition with hPRL, displayed undistinguishable pro®les compared to untreated cells (Figure 2b ), indicating that the analog per se has no eect, but that its competitive inhibition of WT hPRL is maintained over a long period. The same analysis was performed using the T-47Dco cell line, and in agreement with WST-1 studies, this cell line appeared more responsive to hPRL stimulation than T-47D cells (31% cells in S/M phase versus 23% after 24 h; Figure  2b ). However, hPRL eect appeared more transient in T-47Dco cells (compare both panels of Figure 2b ). Whatever the type (CSS, FCS, hPRL, antagonist) or the time (24 ± 72 h) of treatment, we failed to detect signi®cant apoptosis of T-47D and T-47Dco cells (always 55% of cells in the sub G 0 /G 1 peak), as illustrated in Figure 2a .
Agonistic and antagonistic properties of hPRL and G129R-hPRL on signaling pathways
In order to validate our experimental procedures (including ecacy of antibodies), dose-response and time-course experiments using WT hPRL were ®rst performed, then we characterized both agonistic and antagonistic activities of G129R-hPRL or A22W-hPRL antagonists in the same conditions. All these experiments were performed using both T-47D and T47Dco cells, and investigation of the MAPK pathway was also performed using three other breast tumor cell lines. Figures 3 ± 5 are representative of the main results obtained from at least two independent experiments for each protein studied.
STAT5b
Treatment of T-47D cells with hPRL induces a rapid activation of STAT5b via phosphorylation of its Cterminal tyrosine (Gouilleux et al., 1994) , which is time-(not shown) and dose-dependent (Figure 3a , left). As previously reported (Schaber et al., 1998) , we failed to detect activation of Stat5a by PRL in T-47D (not shown). Activation of STAT5b is detected in the presence of hPRL concentrations as low as 50 ng/ml after 15 min of stimulation, and this persists for at least 60 min. Conversely, G129R-hPRL had no detectable eect on STAT5b tyrosine phosphorylation, even at 200-fold higher concentrations (10 mg/ml) ( Figure 3a , middle panel). In contrast, it was able to compete with hPRL (50 ng/ml) for STAT5b activation in a dose-dependent manner, with a mutant:hPRL ratio of 10 : 1 sucient to block 490% of detectable STAT5b phosphorylation (Figure 3a , right, and Figure  6 ). When tested in the same conditions, A22W-hPRL analog required higher concentration (200 : 1 ratio versus WT hPRL) to achieve complete inhibition of STAT5b phosphorylation, indicating much weaker antagonistic activity (not shown). Therefore, the experiments reported below only concern G129R-hPRL.
Analysis of STAT5b activation was also performed over a long time (72 h ; Figure 4 ). Using a 5% SDS ± PAGE, we were able to show that hPRL-induced STAT5b phosphorylation persists at least for 72 h, as illustrated by the occurrence of a shift of STAT5b in anti-STAT5b immunoblots, corresponding to tyrosine and/or serine phosphorylated forms of the protein (right panels of Figure 4a ; Kirken et al., 1997) . Again, G129R-hPRL failed to activate STAT5b, even after 48 h treatment, as shown by the absence of shifted band in STAT5b immunoblots (Figure 4b ). Accordingly, its antagonistic properties were maintained over this long term stimulation since no shifted STAT5b was observed at a 10 : 1 mutant:hPRL ratio after 48 h (Figure 4c ).
STAT3 and STAT1
We then analysed the activation of STAT3 (Figure 3b ) and STAT1 (Figure 3c ), two other hPRL targets in the JAK/STAT pathway. In contrast to STAT5b (Figure  3a) , phosphorylation of these STATs by hPRL stimulus was not easily detected using anti-phosphotyrosine antibodies (not shown); therefore we used anti-phospho-STAT speci®c antibodies. Moreover, maximal phosphorylation of STATs 1 and 3 required a higher hormone concentration (0.25 ± 1 mg/ml) compared to STAT5b. Even at a high concentration (10 mg/ml), G129R-hPRL is unable to promote detectable phosphorylation of STAT1 or STAT3 (Figures 3b,c, middle panels) . Accordingly, when added in 10-fold molar excess, it antagonizes hPRL-induced phosphorylation of these STATs (Figures 3b,c , right panels, and Figure 6 ).
MAP kinase pathway
hPRL treatment of T-47D cells induced p44 (Erk1) and p42 (Erk2) phosphorylation after 15 min of stimulation, and this eect persisted at least for 30 min (not shown). Phosphorylation was already detected using 10 ng/ml hPRL to reach its maximum at 1 mg/ml (Figure 5a, left panel) . The G129R-hPRL analog is intrinsically unable to activate this signaling pathway (Figure 5a , middle panel), but competitively inhibits Figure 3 Agonism and antagonism of hPRL and G129R-hPRL on STAT activation. T-47D cells were treated with indicated doses of hPRL or G129R-hPRL (Agonism) or both combined (Antagonism) for 15 min. Then each STAT (immunoprecipitated or from total cell lysates) was analysed by immunoblotting using anti-phosphotyrosine or STAT phosphospeci®c antibodies. Membranes were stripped and reprobed with appropriate anti-STAT antibodies to check equal loading (lower panels). Agonism of PRL is shown on the left panels, agonism of G129R-hPRL on middle panels, and antagonism of G129R-hPRL on right panels. (a) STAT5b was immunoprecipitated from lysates and blotted using antiphosphotyrosine 4G10 antibodies. (b) STAT3 was immunoprecipitated from lysates and immunobloting was performed using anti-phospho-STAT3 antibodies. Note the weak phosphorylation of STAT3 in basal conditions. (c) Fifty mg of total cell lysates were analysed by immunoblotting using speci®c antityrosine-phosphorylated STAT1 antibodies, which recognize both a and b isoforms of STAT1. Symbols: P-STAT5b, P-STAT3, P-STAT1: tyrosine-phosphorylated STAT factors; IgG H : heavy chain of the antibody used for immunoprecipitation; arrowheads indicate the concentration of antagonist required to achieve 490% inhibition of detectable phosphorylation hPRL-induced phosphorylation of Erk1 and Erk2 in a dose-dependent manner (Figure 5a, right panel) . Signi®cant inhibition of Erk phosphorylation was already observed at a 10 : 1 ratio of mutant:hPRL, and 490% inhibition of both MAPK required a *50-fold molar excess of the analog (Figure 6 ).
Antagonistic properties of G129R-hPRL on other breast cancer cell lines
In order to con®rm observations made using T-47D cells, we analysed the antagonistic properties of G129R-hPRL on JAK/STAT and MAPK signaling cascades in other breast tumor cell lines diering by their hPRL binding capacity (not shown) and their estrogen receptor status (see Materials and methods).
G129R-hPRL antagonism of hPRL-induced activation of STAT5b (not shown) or MAPK (Figure 5b , left) using the estrogen-resistant T-47Dco cell line was very similar to that observed for the ER + T-47D cell line (Figures 3a and 5a) . Using the ER + MCF-7 cell line (Figure 5b , middle) and the estrogen insensitive BT-20 cell line (Figure 5b, right) , a still more ecient antagonism of hPRL-induced MAPK phosphorylation was observed since a 5 : 1 to 10 : 1 ratio of analog versus hPRL was sucient to achieve 490% inhibition. Finally, neither agonistic eect of hPRL nor antagonistic eect of G129R-hPRL could be detected using MDA-MB 231 cells due to the very high basal level of MAPK phosphorylation in this particular cell line (not shown), as previously reported (Zhou et al., 1998) .
Discussion
During the past 5 years, several studies have provided novel evidence for the involvement of hPRL on human breast cancer, probably via an autocrine/ paracrine loop (Ginsburg and Vonderhaar, 1995; Clevenger and Plank, 1997; Gon et al., 1999a; Wennbo and Tornell, 2000) . This new way to consider the possible role of hPRL in human breast carcinogenesis led to the concept that hPRLR antagonists may be useful to reverse its proliferative eect. In this study, we show that hPRL analogs engineered to interfere with hPRLR dimerization act as hPRL antagonists on breast cancer cells. In agreement with our previous reports (Gon et al., 1994 (Gon et al., , 1996b , G129R-hPRL is a more potent antagonist than A22W-hPRL, presumably because the latter alters, Figure 4 Agonism and antagonism of hPRL and G129R-hPRL on long term activation of STAT5b. (a) Total lysates of T-47D cells treated with various doses of hPRL for 30 min to 72 h were analysed using anti-STAT5b antibodies on a 5% SDS ± PAGE. As shown on STAT5b immunoprecipitates (a, right), activated STAT5b is shifted due to phosphorylation on tyrosine (and serine; not shown). (b) G129R-hPRL failed to activate STAT5b, even after 48 h treatment. (c) A 10-fold molar excess of G129R-hPRL inhibits hPRL-induced STAT5b activation after 48 h of treatment, indicating that the antagonism is maintained over a long time stimulation but does not completely prevent receptor dimerization. Using two dierent approaches (WST-1 survival assay and cell cycle analysis), we show that G129R-hPRL competitively abolishes the mitogenic eect of hPRL when used in 10-fold molar excess. This is clearly justi®ed by its *1 log lower receptor anity compared to the native hormone, according to our former observations (Kinet et al., 1999) . A few years ago, Fuh and Wells (1995) reported that hGH and hPL analogs mutated at binding site 2 can also prevent lactogen-induced proliferation of human breast cancer cells. However, the antagonistic properties of these analogs were shown to be very modest on cell lines expressing a high number of hPRLR, such as T-47D cells, since only 12% inhibition of thymidine incorporation could be obtained, and this required much higher concentrations of hormone analogs . Although direct comparison of their study with our data may be biased due to the use of dierent experimental procedures for monitoring cell proliferation, it is reasonable to speculate that the inhibition of T-47D and T-47Dco cell proliferation by G129R-hPRL antagonist is more eective than that obtained with hGH antagonists. Moreover, hGH antagonists are probably unsuitable with the aim of being used in breast cancer therapy since they potentially interact with both lactogen (PRLR) and somatogen (GHR) receptors (Fuh et al., 1992 (Fuh et al., , 1993 . Although a GHR-speci®c hGH antagonist (referred to as B2036) has been designed by combinatorial mutagenesis and is currently in clinical trials for treatment of pathologies linked to excess-hGH secretion (Gon et al., 1999b , and references therein), we are not aware of any engineered PRLR-speci®c hGH antagonist. Obviously, a hPRL analog lacking somatogenic binding ability could ful®l this role. Fifty mg of total cell lysates were loaded on a 10% SDS-polyacrylamide gel, and analysed by immunoblotting using anti-threonine/tyrosine-phosphorylated-Erk1/2 speci®c antibodies. Membranes were stripped and reprobed using anti-Erk1/2 MAPK antibodies to check equal loading (lower panels). Agonism of hPRL and G129R-hPRL is shown on the left panels, and antagonism of G129R-hPRL on the right panels. (b) Antagonism of G129R-hPRL on various human breast cancer cell lines. Activation of MAPK in various breast cancer cell lines diering by their ER status was analysed as described in a. Left: T-47Dco cells, reported to be estrogen-insensitive despite of the expression of ER (Horwitz, 1985) . Middle: MCF-7 (ER + ). Right: BT-20, expressing a mutated, non functional ER. Inhibition of hPRL-activated MAPK pathway by G129R-hPRL is observed in all cell lines irrespective of their ER status. Symbols: P-Erk1/2: threonine/tyrosine-phosphorylated Erk1/2; arrowheads indicate the concentration of antagonist required to achieve 490% inhibition of detectable phosphorylation Despite of the high interest of their pioneering study, Fuh and Wells (1995) did not investigate the intracellular events involved in the inhibitory properties of hPRLR antagonists, which is detrimental to our understanding of the cellular responses that are aected by these hormone analogs (e.g. decreased proliferation versus increased apoptosis). With the aim of elucidating the molecular mechanisms by which G129R-hPRL antagonizes hPRL actions, we analysed its eect on proteins involved in signaling pathways triggered by the hPRLR in human mammary epithelial cells. Since previous reports based on signaling studies and use of kinase inhibitors, showed that the mitogenic activity of hPRL on mammary cells involves the JAK-STAT and the MAPK pathways Vonderhaar, 1996a,b, 1997) , we focused our studies on these two major cascades. Whatever the molecular target considered (STAT1, STAT3, STAT5b, Erk1, Erk2), G129R-hPRL is able to eciently prevent hPRLinduced activation of these cascades when present in *10-fold molar excess, thus paralleling observations made in proliferation studies. Since both hPRL and G129R-hPRL bind to the same receptor and since the antagonist is devoid of intrinsic agonistic eect, whatever the response investigated, its inhibitory action on hPRL-mediated eects occurs through a competitive mechanism. Interestingly, long-term analysis of STAT5b activation in T-47D cells provides evidence that this competitive inhibitory eect cannot be overcome by hPRL even over a long period of time, corroborating at the molecular level the observations made by cell cycle analysis studies (Figure 2b, upper panel) . Due to the high genetic variability of breast cancer cell lines, we included other breast cancer cell lines in our study to give a broader relevance to our ®ndings and a similar antagonistic eect of G129R-hPRL was observed.
In breast tumors, an increase of STAT1 and STAT3 activation has been reported (Watson and Miller, 1995) , but identi®cation of the extracellular stimuli involved is still to be explored. In addition, STAT3 appears involved in c-Src oncogenesis (Turkson et al., 1998) and is constitutively active in some breast tumors (Garcia et al., 1997) , which suggests an important role for this STAT in breast carcinogenesis. We also observed a weak basal phosphorylation of this STAT factor in T-47D cells. Thus, inhibition of STATs 1 and 3 by hPRL antagonists at a 10 : 1 ratio appears particularly relevant in the context of mammary tumors. Other pathways than the MAPK and JAK/ STAT cascades are also activated by hPRL in mammary cells and may partly account for the promoting role of the hormone in breast tumors. Recently, the group of Clevenger showed that hPRL is chemoattractant for human breast carcinomas, and may thereby facilitate breast cancer metastasis, which frequently arise from in lymph node, a site rich in Tlymphocytes capable of producing hPRL (Maus et al., 1999) . Such a hPRL-induced cell mobility may involve the Focal Adhesion Kinase pathway, whose activation by hPRL has been shown in T-47D cells (Canbay et al., 1997) . Since G129R-hPRL acts by interfering with functional receptor homodimerization (Gon et al., 1996b; Kinet et al., 1999) , a step which appears to be a pre-requisite for most (if not all) hPRLR-triggered eects, it is reasonable to anticipate that the analog will also antagonize these hPRL-induced phenomena, although this assumption awaits experimental evidence. In view of ®rst, the historically described relationship between the MAPK pathway and cell proliferation, and second, the more recent ®ndings showing crosstalk between MAPK and JAK/STAT pathways, the antagonistic properties of G129R-hPRL observed in mammary tumor cells may potentially be extended to other PRL-modulated tumors, e.g. prostate cancers (Melck et al., 2000) , where these same major signaling cascades have been shown to be involved (Price et al., 1999; Lou et al., 2000) .
Besides deciphering some molecular bases of the anti-proliferative properties of our hPRL antagonist, another important issue raised in this work is the unambiguous demonstration that G129R-hPRL per se lacks signi®cant ability to activate the hPRLR. Based on former characterization of PRL/GH analogs impaired at binding site 2, this observation was expected and it con®rms that no other eect than blocking wild type hormone is anticipated for this mutant (Wells, 1996; Gon et al., 1996a) . This is in total contrast with data recently reported by Chen et al. (1999) , who claimed that the same antagonist as the one reported here inhibits T-47D cell proliferation by promoting apoptosis, independently of addition of exogenous hPRL. Although the putative molecular mechanisms involved in this eect have yet to be elucidated, two hypotheses can be proposed. The induction of apoptosis implies that the antagonist activates signaling machinery leading to cell death. This result is diametrically opposed to our observations which clearly show that G129R-hPRL lacks signaling ability, whatever the molecular target analysed. Moreover, since hPRL has been shown to exert an anti-apoptotic role in lymphoid cells (Krumenacker et al., 1998) and potentially in mouse mammary cells (Gordon et al., 2000) , this would imply that the hPRLR may transmit opposite signals depending on the ligand, which is very unlikely. On the other hand, the decrease of cell number observed by Chen et al. (1999) in the presence of G129R-hPRL more probably re¯ects the competitive inhibition of the proliferative eect exerted by endogenous hPRL, as previously observed using anti-hPRL antibodies (Ginsburg and Vonderhaar, 1995) . Unfortunately, the reliability of this hypothesis was not assessed by the authors since no information on the concentration of hPRL present in cell culture supernatant was provided in their study (Chen et al., 1999) . Nevertheless, we were surprised to discover that DNA fragmentation was detected by TUNEL assay after as short as 2 h of incubation with the antagonist, since this morphological hallmark of apoptotis is known to occur later in the apoptotic process and usually requires a longer time of exposure to the pro-apoptotic conditions (Saraste, 1999) . In addition, using cell cycle analysis, we failed to detect evidence for induction of apoptosis by G129R-hPRL using similar conditions (0.5% CSS), even after 72 h of incubation. This ®nding is not surprising since T-47D/T-47Dco tumor cell lines have not been reported to be dependent on PRL for survival. These contradictory observations question the physiological relevance of the pro-apoptotic role of G129R-hPRL claimed by others (Chen et al., 1999) ; elucidation of the putative role of this antagonist on programmed cell death obviously awaits for further studies. Molecular evidence that proteins known to regulate apoptosis or survival (e.g. Bcl-2 protein family) are activated or repressed by G129R-hPRL would certainly clarify this issue.
In conclusion, breast cancer therapy has long been focused on the development of anti-estrogen drugs, because estrogen was the only hormonal factor clearly implicated in human breast tumorigenesis. However, such a predominant role of estrogens in breast tumor progression does not preclude the involvement of other hormones. In addition, although drugs such as Tamoxifen have been proven to be very eective on breast cancer prevention and treatment, a fraction of tumors progress to drug resistance which renders antiestrogen drugs inecient. Clinical treatment of these cases awaits for further development of new therapeutic approaches. Lately, the involvement of hPRL on human breast cancer is being reconsidered (Vonderhaar, 1998; Gon et al., 1999a) . In this paper, we have reported that G129R-hPRL acts as an antagonist on several human breast cancer cell lines, irrespective to their ER status, suggesting that hPRL antagonists may be used in anti-estrogen insensitive breast tumors. For the ®rst time, we provide evidence at the molecular level on the mechanism of action of these antagonists, which lack intrinsic signaling capacity but speci®cally inhibit hPRL-activated signaling cascades involved in cell proliferation. Due to its slightly lower anity for the hPRLR, a 10-fold molar excess of the antagonist is necessary to achieve inhibition of hPRL action. With the aim of improving this eciency, our group is actively working on the design and development of more potent hPRL antagonists by searching for alternative strategies to increase their receptor binding anity.
Materials and methods

Cells
T-47D cells were kindly provided by Michael Norman (Bristol, UK), and the T-47Dco subline was obtained from Barbara Vonderhaar (NCI, Bethesda, USA). Both are human breast cancer epithelial cells derived from an in®ltrating ductal carcinoma. The T-47D clone is estrogen receptor (ER) positive, whereas the T-47Dco clone was reported to be estrogen-insensitive (Horwitz, 1985) . Cells were routinely cultured in DMEM/F12 (1 : 1) medium containing 10% fetal calf serum (FCS), 2 mM glutamine, penicillin (50 U/ml) and streptomycin (50 mg/ml), using a humidi®ed 378C incubator under 5% CO 2 . They were split 1/4 every 3 ± 4 days using standard methods. BT-20, MCF-7 and MDA-MB 231 breast cancer cell lines were kindly provided by Catherine Mallet (Paris, France) and were routinely cultured in DMEM medium (glucose content was 4.5 g/l for MCF-7 and MDA-MB 231 and 1 g/l for BT-20) supplemented with 10% FCS, 2 mM glutamine, penicillin (50 U/ml) and streptomycin (50 mg/ml) for all, and with 25 mU/ml of insulin only for BT-20. MCF-7 cells are positive for ER, whereas MDA-MB 231 and BT-20 cells are ER negative (BT-20 cells express a mutated ER with exon 5 deleted).
Hormones
We used only recombinant proteins generated in our laboratory. Wild type hPRL and binding site 2 analogs G129R-hPRL (Gly 129 replaced with Arg) and A22W-hPRL (Ala 22 replaced with Trp) were produced in Escherichia coli and puri®ed routinely as extensively described in previous reports (Paris et al., 1990; Gon et al., 1992) . The monomeric and oxydized proteins (internal disul®de bonds correctly formed) were 495% pure and were quanti®ed by the Bradford method before being used for stimulation of breast cancer cells. The biological activity of recombinant hPRL has previously been shown to be equivalent to that of pituitary-puri®ed hPRL (Gon et al., 1992) .
Antibodies
Polyclonal antibodies against STAT5b and STAT3, together with a monoclonal antibody against STAT1 were purchased from Santa Cruz Biotechnology, Inc., and used at a 1 : 1000 dilution for Western blot analysis. Antibodies speci®c for tyrosine 701 -phosphorylated STAT1 and threonine 202 /tyrosine 204 -phosphorylated MAP kinases 1 and 2 (also referred to as Erk1 and Erk2) were obtained from New England Biolabs Ltd, and used at the dilutions recommended by the supplier. Polyclonal serum directed against MAP kinases 1 and 2, monoclonal antibodies anti-phosphotyrosine (4G10) and tyrosine 704 -phosphorylated STAT3 were from Upstate Biotechnology (Lake Placid, NY, USA), and they were used for immunodetection at dilutions of 1 : 2500, 1 : 10 000 and 1 : 1 000, respectively.
Binding studies
Human PRL was iodinated using iodogen as previously reported (Gon et al., 1992) . Its speci®c activity was in the range of 40 ± 60 mCi/mg. Scatchard analyses of hPRL and G129R-hPRL were performed on cell homogenates prepared as previously described (Gon et al., 1992) . For binding assays, 400 mg of cell proteins were incubated overnight at room temperature with 75 000 c.p.m. [ 125 I]hPRL in DMEM medium containing 0.1% BSA (the ®nal reaction volume was 0.5 ml). The assay was terminated by addition of 0.5 ml icecold buer (25 mM Tris-HCl, 20 mM MgCl 2 , pH 7.4) followed by centrifugation (15 min, 15 000 g). The supernatants were aspirated carefully and the radioactivity of the pellets was counted in a gamma counter. In both types of experiment, speci®c binding was calculated as the dierence between radioactivity bound in the absence (B 0 , maximal binding) and in the presence (non speci®c) of 10 mg/ml unlabelled WT hPRL.
Cell proliferation assays
T-47D and T-47Dco cells were detached in 5 mM EDTA/ PBS, centrifuged and transferred into a 96-well plate in DMEM/F12 medium containing 1% charcoal-stripped serum (CSS). Cell number was determined using a hemocytometer and the optimal cell density was found to be 30 000 cells/well (see Results). Cells were treated by addition of various concentrations of hPRL, WT or analog, alone (agonism) or combined (antagonism), diluted appropriately to get a ®nal volume of 200 ml. Cells were incubated for 3 days at 378C in a humidi®ed 5% CO 2 incubator. After this period, 10 ml of WST-1 cell viability reagent (Boehringer-Mannheim) were added to each well. After a reaction time of 2 ± 4 h, plates were read at 450 nm using a microplate reader (EL-808, Bio-TEK Instruments, Inc.). Experiments were carried out in triplicates and repeated 3 ± 5 times for each condition.
Cell cycle analyses
Adherent cells aliquoted in 6 well plates (0.5 ± 1610 6 cells per well) were serum deprived for 24 h prior addition of hormones or serum. After the indicated times (24 ± 72 h), culture medium was collected to recover¯oating cells by centrifugation, and attached cells were harvested by brief trypsinization. Cells were pooled and permeabilized using 40 ml of DNA-Prep Reagent (Coulter Corp., Miami, FL, USA) prior 30 min incubation at 378C in 0.5 ml of DNA intercalator propidium iodide (DNA-Prep stain propidium iodide). Cell cycle distribution was analysed by¯ow cytometry on a FACScan using CellQuest software (Becton Dickinson, Mountain View, CA, USA) and manual gating.
Cell treatment and preparation of cell lysates
Cells were plated at 50 ± 60% con¯uence in complete medium (10% FCS) in 6-well plates or in 100 mm Petri dishes (for immunoprecipitation studies). They were allowed to adhere to the plate for at least 4 ± 6 h, then they were serum starved for 16 ± 20 h. Next day, medium was replaced by serum-free medium containing various concentrations of hPRL, hPRL antagonist (G129R-hPRL or A22W-hPRL), or both together. Cells were incubated at 378C for the time period indicated in the Figures, after which they were washed twice using ice-cold stopping buer (0.4 mM sodium orthovanadate in PBS). Cells were solubilized in lysis buer (10 mM Tris-HCl pH 7.5, 5 mM EDTA, 150 mM NaCl, 50 mM sodium¯uoride, 30 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl, 1 mg/ml pepstatin A, 2 mg/ml leupeptin, 5 mg/ml aprotinin, 10% glycerol, 0.5% Triton X-100), scraped, transferred into a tube and incubated on ice for 30 min. After clearing the total cell lysate by centrifugation for 10 min at 15 000 r.p.m., protein content of the supernatant was quanti®ed by Bradford assay (Bio-Rad).
Immunoprecipitation and Western blot
Total cell lysates (2 mg protein) were used for immunoprecipitation with the following antibodies: polyclonal antiSTAT5b and polyclonal anti-STAT3 (Santa Cruz Biotechnology, Inc.), used at 1 mg/ml. After 4 h of rotation at 48C, immunocomplexes were captured with 30 ml Protein A Sepharose slurry (50%) (Amersham Pharmacia Biotech, Uppsala, Sweden) by overnight incubation. Protein A complexes were precipitated by centrifugation, pellets were washed three times in lysis buer and then boiled in reducing SDS sample buer for 3 min. Immunoprecipitated samples or total cell lysates (50 mg protein/well) were analysed using 5% or 7.5% (STAT analyses) and 10% (MAPK analyses) SDS ± PAGE, followed by electrophoretic transfer onto nitrocellulose membranes (Bio-Rad). The membranes were blocked with 5% skimmed milk in Tris-buered saline-Tween 20 (TBST) (20 mM Tris-HCl pH 7.6, 137 mM NaCl, 0.1% Tween 20) for 1 ± 2 h at room temperature. After washing in TBST, they were incubated overnight at 48C with 3% bovine serum albumin in TBST containing the primary antibody. The membranes were again washed in TBST and incubated for 1 h with horseradish peroxidase conjugate of a suitable secondary antibody (anti-rabbit or anti-mouse, Amersham Pharmacia Biotech) diluted as recommended by the supplier. After washing as described above, the immunoblots were revealed by ECL (Chemiluminescence kit Renaissance; DuPont-NEN) followed by autoradiography. When required, the membranes were dehybridized using stripping buer (2% SDS, 100 mM b-mercaptoethanol, 62.5 mM Tris-HCl pH 6.8) for 30 min at 508C. After extensive washing and re-blocking, membranes were reprobed with another antibody.
Densitometric analysis of autoradiographies was performed using the image analysis software Scion Image (Scion Corporation, MD, USA).
